KG&L Capital Management LLC Has $4.19 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

KG&L Capital Management LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 4.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,733 shares of the company’s stock after purchasing an additional 182 shares during the period. Eli Lilly and Company makes up 1.4% of KG&L Capital Management LLC’s investment portfolio, making the stock its 17th biggest holding. KG&L Capital Management LLC’s holdings in Eli Lilly and Company were worth $4,193,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Robeco Institutional Asset Management B.V. raised its holdings in shares of Eli Lilly and Company by 14.5% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 826,944 shares of the company’s stock worth $732,623,000 after acquiring an additional 104,801 shares during the last quarter. Lansing Street Advisors raised its holdings in shares of Eli Lilly and Company by 3.3% in the 3rd quarter. Lansing Street Advisors now owns 648 shares of the company’s stock worth $575,000 after acquiring an additional 21 shares during the last quarter. BSW Wealth Partners raised its holdings in shares of Eli Lilly and Company by 4.3% in the 3rd quarter. BSW Wealth Partners now owns 3,236 shares of the company’s stock worth $2,867,000 after acquiring an additional 134 shares during the last quarter. Angeles Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 9.0% in the 3rd quarter. Angeles Wealth Management LLC now owns 4,804 shares of the company’s stock worth $4,256,000 after acquiring an additional 397 shares during the last quarter. Finally, Emerald Advisers LLC raised its holdings in shares of Eli Lilly and Company by 75.2% in the 3rd quarter. Emerald Advisers LLC now owns 1,873 shares of the company’s stock worth $1,659,000 after acquiring an additional 804 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on LLY shares. Citigroup upped their target price on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a report on Friday, October 25th. Wells Fargo & Company increased their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Barclays decreased their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research note on Thursday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $1,025.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Finally, JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Friday, September 13th. Three investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,009.00.

Eli Lilly and Company Trading Down 1.3 %

NYSE:LLY opened at $818.93 on Monday. The company has a market cap of $777.43 billion, a P/E ratio of 88.53, a P/E/G ratio of 3.13 and a beta of 0.43. The stock’s fifty day moving average price is $911.04 and its two-hundred day moving average price is $866.97. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.87.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company’s revenue was up 20.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 EPS. As a group, analysts expect that Eli Lilly and Company will post 13.23 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.63%. Eli Lilly and Company’s payout ratio is currently 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.